The Pharma Letter speaks to Sjaak Vink, the chief executive of the SocialMedwork, a bold and ambitious start-up that wants to stop borders being a barrier for patients. 26 January 2018
In a highly informative and useful Expert View piece, Heather Longden, senior marketing manager for informatics regulatory compliance at the analytical laboratory instrument and software company Waters Corporation, provides insights into the vital role data integrity plays when it comes to analytical testing for drug development. 26 January 2018
A long-standing leader in health technology assessment (HTA) in the UK and internationally has taken a step across the divide to become a leading lobbyist for pharma. 25 January 2018
Belgian biotech firm Ablynx today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018. 24 January 2018
In the first of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, senior executives from Boehringer Ingelheim, Teva Pharmaceutical Industries and Pfizer ask how pharma waving goodbye to brand-led strategies is changing relationships with HCPs. 24 January 2018
Merck & Co UK unit MSD has today announced the appointment of Dr Fiona Marshall to lead its new discovery research facility in London, focused on early bioscience discovery and entrepreneurial innovation. 22 January 2018
For years, China has been viewed with a mixture of excitement, optimism and suspicion by western pharmaceutical firms, with nervous investors wary of the relatively opaque political and economic environment in the country. 22 January 2018
Japanese GPCR medicines specialist Sosei Group today announced that Dr Fiona Marshall has resigned from her position as executive vice president and chief scientific officer of Sosei to assume a senior role outside the company. 19 January 2018
The cost of prescription drugs is at the forefront of discussions among patients, advocacy groups, prescribers, payers, pharmaceutical companies, and policy makers. One factor – though not the only factor – in driving the cost of prescription drugs is the availability of competing products. 19 January 2018
Jordan-headquartered Hikma Pharmaceuticals today announced that Surendera Tyagi will join the company as group chief scientific officer and global head of R&D. 15 January 2018
The Russian government has announced that it will provide subsidies for domestic drugmakers and foreign companies operating in the local market for the partial cover their costs, associated with the forthcoming introduction of labeling procedure in the domestic pharmaceutical market, reports The Pharma Letter’s local correspondent. 13 January 2018
With sales of 97 billion yen ($970 million) for the first half of 2017, a rise of nearly 50% on the previous year, the gastroenterology product Entyvio (vedolizumab) is the best-selling brand of Japanese pharma major Takeda Pharmaceutical. 11 January 2018
Novartis today revealed that Elizabeth (Liz) Barrett, currently global president oncology at Pfizer, will join the company as chief executive of Novartis Oncology and a member of the executive committee of Novartis, effective February 1, 2018 11 January 2018
This year marks the 350th anniversary of German science and technology group Merck KGaA, a milestone that will remind the industry and wider world that it is the oldest operating pharma company in existence anywhere. 10 January 2018
According to US Food and Drug Administration regulations, the regulatory agency may refuse to file a new drug application (NDA) or biologics license application (BLA) when either is deemed incomplete, writes Dr Nicola Davies in her monthly blog for The Pharma Letter. 10 January 2018
French drugmaker Ipsen today announced the promotion of Dr Aidan Murphy as executive vice president, technical operations, effective January 1, 2018. 10 January 2018
Andrew Rut, chief executive of MyMeds&Me, a provider of adverse event and product quality capture software, considers in an Expert View piece how pharma’s ability to run efficient clinical trials is in danger of being compromised by GDPR and a hardening of attitudes on data privacy globally. 9 January 2018
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news